<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01974258</url>
  </required_header>
  <id_info>
    <org_study_id>GO29026</org_study_id>
    <nct_id>NCT01974258</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients</brief_title>
  <official_title>A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB IN COMBINATION WITH VEMURAFENIB AND/OR COBIMETINIB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will evaluate the maximum tolerated dose and dose-limiting toxicities of&#xD;
      vemurafenib and/or cobimetinib when used with onartuzumab in cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of dose-limiting toxicities (DLTs) of vermurafenib and/or cobimetinib used in combination with onartuzumab.</measure>
    <time_frame>24 to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence of anti-therapeutic antibodies against onartuzumab.</measure>
    <time_frame>24 to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events (AE)</measure>
    <time_frame>24 to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum concentration (Cmax) of onartuzumab</measure>
    <time_frame>24 to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum concentration (Cmax) of cobimetinib</measure>
    <time_frame>24 to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum concentration (Cmax) of vemurafenib</measure>
    <time_frame>24 to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Overall response rate</measure>
    <time_frame>24 to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Progression-free survival</measure>
    <time_frame>24 to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Duration of response</measure>
    <time_frame>24 to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Overall survival</measure>
    <time_frame>24 to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dose-expansion: onartuzumab + cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-expansion: onartuzumab + vemurafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-expansion: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-finding: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Escalating dose</description>
    <arm_group_label>Dose-finding: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Orally administered once daily for 21 consecutive days, followed by 7 days off.</description>
    <arm_group_label>Dose-expansion: onartuzumab + cobimetinib</arm_group_label>
    <arm_group_label>Dose-expansion: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onartuzumab</intervention_name>
    <description>Administered by IV infusion every 2 weeks</description>
    <arm_group_label>Dose-expansion: onartuzumab + cobimetinib</arm_group_label>
    <arm_group_label>Dose-expansion: onartuzumab + vemurafenib</arm_group_label>
    <arm_group_label>Dose-expansion: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
    <arm_group_label>Dose-finding: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>Orally administered twice daily</description>
    <arm_group_label>Dose-expansion: onartuzumab + vemurafenib</arm_group_label>
    <arm_group_label>Dose-expansion: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
    <arm_group_label>Dose-finding: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients &gt;/= 18 years of age.&#xD;
&#xD;
          -  Patients with histologically confirmed, BRAFV600-mutant, unresectable, locally&#xD;
             advanced or metastatic solid malignancies. OR&#xD;
&#xD;
          -  Patients with a histologically confirmed, KRAS-mutant, Stage IV colorectal&#xD;
             adenocarcinoma, or KRAS-mutant metastatic non-small-cell lung carcinoma. OR&#xD;
&#xD;
          -  Patients with histologically confirmed BRAFV600-mutant unresectable Stage IIIC or&#xD;
             Stage IV metastatic melanoma.&#xD;
&#xD;
          -  Valid MET IHC test result.&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors v1.1&#xD;
&#xD;
          -  ECOG performance status of 0 or 1.&#xD;
&#xD;
          -  For BRAFV600-mutant cancers:&#xD;
&#xD;
          -  Previously untreated for their melanoma or previously treated for their melanoma but&#xD;
             without prior exposure to any HGF, MET, BRAF, or MEK inhibitor therapy&#xD;
&#xD;
          -  BRAFV600-mutant solid malignancies other than melanoma for which standard therapy does&#xD;
             not exist has proven to be ineffective or intolerable or is considered inappropriate.&#xD;
&#xD;
        Patients must not have had prior exposure to HGF, MET, BRAF, or MEK inhibitor therapy.&#xD;
&#xD;
          -  For KRAS-mutant cancers:&#xD;
&#xD;
          -  mCRC patients must have received therapeutic regimens including oxaliplatin,&#xD;
             irinotecan, 5-FU, and bevacizumab, or determined to be ineligible for these&#xD;
             treatments. Patients must not have had prior exposure to HGF, MET, BRAF, or MEK&#xD;
             inhibitor therapy.&#xD;
&#xD;
          -  Metastatic NSCLC patients must have received platinum-based doublet chemotherapy or&#xD;
             determined to be ineligible for this regimen. Patients must not have had prior&#xD;
             exposure to HGF, MET, BRAF, or MEK inhibitor therapy.&#xD;
&#xD;
          -  Consent to provide tumor tissue for biomarker analyses.&#xD;
&#xD;
          -  Life expectancy &gt;/= 12 weeks.&#xD;
&#xD;
          -  Fully recovery from the effects of any major surgery or significant traumatic injury&#xD;
             within 14 days from the first dose of study treatment.&#xD;
&#xD;
          -  Adequate hematologic and end organ function, as defined by clinical laboratory&#xD;
             results.&#xD;
&#xD;
          -  Use of effective form(s) of contraception as defined by protocol during the course of&#xD;
             this study and for at least 6 months after study drug discontinuation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Palliative radiotherapy or experimental therapy within 28 days prior to first dose of&#xD;
             study drug treatment.&#xD;
&#xD;
          -  Major surgical procedure or significant traumatic injury from 28 days prior to first&#xD;
             dose of study drug treatment until end of study.&#xD;
&#xD;
          -  History of another malignancy in the previous 5 years, unless cured by surgery alone&#xD;
             and continuously disease free. Exceptions include appropriately treated cervical&#xD;
             carcinoma in situ, non-melanoma skin carcinoma, Stage I uterine cancer, localized&#xD;
             prostate cancer that has been treated surgically and is presumed cured, or other&#xD;
             malignancies with an expected curative outcome.&#xD;
&#xD;
          -  Brain metastasis or spinal cord compression not definitively treated with surgery&#xD;
             and/or radiation, or previously diagnosed and treated central nervous system (CNS)&#xD;
             metastases or spinal cord compression without evidence of clinically stable disease&#xD;
             for more than 14 days.&#xD;
&#xD;
        Note: Patients with treated CNS metastases who are asymptomatic and on a stable dose of&#xD;
        corticosteroids for more than 14 days prior to Cycle 1 Day 1 are eligible.&#xD;
&#xD;
          -  For patients given cobimetinib: Evidence of visible retinal pathology that is&#xD;
             considered a risk factor for neurosensory detachment, retinal vein occlusion, or&#xD;
             neovascular macular degeneration, or of conditions that are risk factors for retinal&#xD;
             vein occlusion.&#xD;
&#xD;
          -  Current or history of clinically significant cardiac or pulmonary dysfunction.&#xD;
&#xD;
          -  Lack of recovery to Grade 1 or better from adverse events due to investigational or&#xD;
             other agents administered more than 28 days prior to enrollment, except for alopecia.&#xD;
&#xD;
          -  Current severe, uncontrolled systemic disease.&#xD;
&#xD;
          -  Inability or unwillingness to swallow pills.&#xD;
&#xD;
          -  History of malabsorption or other condition that would interfere with gastrointestinal&#xD;
             absorption of study drug.&#xD;
&#xD;
          -  History of clinically significant liver disease, current alcohol abuse, or known&#xD;
             infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV).&#xD;
&#xD;
          -  Severe (Grade 3 and above) active infection at enrollment, or other serious underlying&#xD;
             medical conditions.&#xD;
&#xD;
          -  Required medication known to cause edema and/or cardiac failure.&#xD;
&#xD;
          -  Active autoimmune disease.&#xD;
&#xD;
          -  Uncontrolled ascites requiring weekly, large-volume paracentesis for 3 consecutive&#xD;
             weeks prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>October 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2013</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vemurafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

